Risk of Liver Cancer From Major Causes Compared to Smoking and Lung Cancer: A Systematic Review and Meta-Analysis.

J Viral HepatSep 1, 2026
Clinical ResearchGastroenterologyOncology (Medical)Open access

Carolyn Wallace, Devin Razavi-Shearer, Samantha Hall et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the risk of liver cancer associated with HBV, HCV, HDV, MASH, and alcohol consumption compared to smoking and lung cancer. Analyzing 126 studies with over 86 million participants, the study found that HBV (OR 15.2), HCV (OR 12.8), and HDV (OR 23.5) significantly increased liver cancer risk compared to smoking (OR 6.0).

Key findings

  • HBV was associated with a liver cancer risk of OR 15.2.
  • HCV showed a liver cancer risk of OR 12.8.
  • HDV had the highest liver cancer risk at OR 23.5.
  • MASH and alcohol use were associated with lower liver cancer risks of OR 2.6 and OR 2.4, respectively.

Why it matters

Understanding the comparative risks of liver cancer from viral hepatitis versus smoking is crucial for public health strategies. This knowledge can enhance awareness and prevention efforts for liver cancer, which is increasingly prevalent.

Source

PubMed · PMID 42605247Free full text on PubMed Central

Published in J Viral Hepat. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.